Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 1758-1767

  Han, Dengfeng ^a   Ma, Jianhua ^a   Zhang, Xiaoning ^a   Cai, Jian ^a   Li, Jinlan ^a   Tuerxun, Tuerhong ^a   Hao, Chenguang ^a   Du, Lei ^a   Lei, Jing ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Ethnic groups; Ischemic attack; Proprotein convertases; Transient

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ADULT; ALLELE; ARTICLE; BRAIN ISCHEMIA; CASE CONTROL STUDY; CHEMICAL ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; DRINKING; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN PROPROTEIN CONVERTASE SUBTILISIN GENE; KEXIN9 GENE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; CEREBROVASCULAR ACCIDENT; ETHNIC GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; STATISTICAL MODEL;

ALLELES; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; STROKE;

EID: 84908142482     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.892091     Document Type: Article

References (35)

1. Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS medicine, 2006; 3: e442
2. Hobbs HH, Russell DW, Brown MS, Goldstein JL: The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet, 1990; 24: 133–70
3. Park SW, Moon YA, Horton JD: Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem, 2004; 279: 50630–38
4. Benjannet S, Rhainds D, Essalmani R et al: NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol chem, 2004; 279: 48865–75
5. Peterson AS, Fong LG, Young SG: PCSK9 function and physiology. J Lipid Res, 2008; 49: 1595–99
6. Horton JD, Cohen JC, Hobbs HH: PCSK9: a convertase that coordinates LDL catabolism. J Lipid Re, 2000; 50(Suppl.): S172–77
7. Horton JD, Cohen JC, Hobbs HH: Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci, 2007; 32: 71–77
8. Folsom AR, Peacock JM, Boerwinkle E: Atherosclerosis Risk in Communities Study I (2009) Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease. Atherosclerosis, 202: 211–15
9. Abifadel M, Varret M, Rabes JP et al: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet, 2003; 34: 154–56
10. Aung LH, Yin RX, Miao L et al: The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis, 2011; 10: 5
11. Chen SN, Ballantyne CM, Gotto AM Jr et al: A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol, 2005; 45: 1611–19
12. Abboud S, Karhunen PJ, Lutjohann D et al: Proprotein convertase subtilisin/ kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke. PloS one, 2007; 2: e1043
13. Norata GD, Garlaschelli K, Grigore L et al: Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis, 2010; 208: 177–82
14. Kotowski IK, Pertsemlidis A, Luke A et al: A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet, 2006; 78: 410–22
15. Polisecki E, Peter I, Robertson M et al: Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis, 2008; 200: 95–101
16. Scartezini M, Hubbart C, Whittall RA et al: The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clin Sci, 2007; 113: 435–41
17. Evans D, Beil FU: The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women. BMC Med Genet, 2006; 7: 66
18. Yue P, Averna M, Lin X, Schonfeld G: The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Hum Mutat, 2006; 27: 460–66
19. Miyake Y, Kimura R, Kokubo Y et al: Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis, 2008; 196: 29–36
20. American Diabetes Association: clinical practice recommendations 1997. Diabetes Care, 1997; 20: S1–S70
21. Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res, 2005; 15: 97–98
22. Li Z, Zhang Z, He Z et al: A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res, 2009; 19: 519–23
23. Seidah NG, Benjannet S, Wickham L et al: The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA, 2003; 100: 928–33
24. Lambert G, Charlton F, Rye KA, Piper DE: Molecular basis of PCSK9 function. Atherosclerosis, 2009; 203: 1–7
25. Schmidt RJ, Beyer TP, Bensch WR et al: Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem Biophys Res Commun, 2008; 370: 634–40
26. Ouguerram K, Chetiveaux M, Zair Y et al: Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol, 2004; 24: 1448–53
27. Sun XM, Eden ER, Tosi I et al: Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet, 2005; 14: 1161–69
28. Allard D, Amsellem S, Abifadel M et al: Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat, 2005; 26: 497
29. Leren TP: Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet, 2004; 65: 419–22
30. Hallman DM, Srinivasan SR, Chen W et al: Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study). Am J Cardiol, 2007; 100: 69–72
31. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR: The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis, 2007; 193: 445–48
32. Benjannet S, Rhainds D, Hamelin J et al: The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem, 2006; 281: 30561–72
33. Lagace TA, Curtis DE, Garuti R et al: Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest, 2006; 116: 2995–3005
34. Lambert G, Jarnoux AL, Pineau T et al: Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology, 2006; 147: 4985–95
35. Slimani A, Harira Y, Trabelsi I et al: Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort. J Mol Neurosci, 2014; 53(2): 150–57